LEP
EmergingLeptin regulates appetite; rare congenital deficiency is treatable with metreleptin replacement therapy.
Leptin tells the brain when you're full. A very rare genetic condition causes leptin deficiency and severe childhood obesity, treatable with a replacement hormone drug. This is different from typical obesity, where leptin is actually high but the brain doesn't respond to it properly.
Leptin (LEP) is a hormone produced by adipose tissue that regulates appetite and energy balance by signaling satiety to the hypothalamus.
Rare congenital leptin deficiency causes severe early-onset obesity from unchecked appetite; more commonly, leptin is studied as a general marker of adipose tissue mass and metabolic status, though "leptin resistance" (high leptin without appetite suppression) is common in typical obesity.
Measured via serum immunoassay; congenital leptin deficiency is confirmed via genetic testing (LEP gene mutations) when clinical suspicion is high (extreme early-onset obesity with very low or undetectable leptin, unlike typical obesity where leptin is elevated).
Rare congenital leptin deficiency is treated with metreleptin, a recombinant leptin replacement therapy — one of the few situations where a hormone deficiency this specific has its own approved replacement drug, distinct from leptin's much more common role as a general obesity/metabolic research marker where replacement doesn't work due to resistance rather than deficiency.
One of the few specific hormone deficiencies with its own approved replacement drug (metreleptin).
- General endocrinology reference literature on congenital leptin deficiency and metreleptin replacement therapy.